Type 1 Diabetes TrialNet
Type 1 Diabetes TrialNet, supported by the National Institutes of Health and other funding agencies, is an international consortium of researchers dedicated to the study, prevention, and early treatment of Type 1 diabetes. Since inception, Type 1 Diabetes TrialNet has screened over 100,000 people for Type 1 diabetes risk.
The UF Health Diabetes Institute is home to TrialNet at UF, a T1D clinical research center which oversees 17 affiliate sites. The mission of the University of Florida TrialNet team is to identify family members at risk, and evaluate promising new therapies to prevent, slow or reverse the progression of the disease. The Pathway to Prevention study offers a blood test that can identify the risk for Type 1 diabetes up to 10 years before symptoms actually appear. UF TrialNet researches have screened over 3,200 participants in this study, with the hopes of reducing complications and helping countless others at risk for Type 1 diabetes.
Click here to learn more.
HealthStreet Gainesville and TrialNet at UF work together to enhance community-based recruitment:
HealthStreet is a community engagement program aiming to reduce disparities in healthcare and research by linking the medically underserved to medical and social services and opportunities to participate in research. Since October 2011, more than 4,700 persons from the Gainesville community have been assessed by Community Health Workers for their needs and concerns through the HealthStreet program. Importantly, assessment of their health concerns revealed the top five to be hypertension, diabetes, overweight/obesity, heart disease and cancer.